Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions around the article emphasize its impactful findings, such as comments on how Paxlovid, which includes nirmatrelvir and ritonavir, effectively inhibits the virus's replication process. Notable phrases like 'HUGE NEWS!!!' and 'exciting to have Paxlovid' reflect a positive tone and eagerness among participants. The language used—highlighting effectiveness, safety, and innovative mechanisms—reinforces strong interest and perceived impact of the research.
Most discussions reflect support for the findings of the publication, highlighting the promise of the new medication.
There is a strong interest, with many users eager to share insights and further information regarding the drug.
Several users delve into scientific details, discussing mechanisms of action and clinical implications, reflecting high engagement.
The consensus is that the publication represents a significant advancement in COVID-19 treatment, with users expressing optimism about its effects.
4/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each other by the protease the virus becomes defective. Paxlovid grabs the protease and neutralizes it & stops the virus from replicating. https://t.co/fTC1PZxqGP
HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathleen Cheasty for hosting and editing! Parts 1-3: https://t.co/BFnAStQVVn https://t.co/mFovLERF35 https://t.co/Wo7cnPQ8OF https://t.co/QQwcjFNP8R
PROTEASE INHIBITORS FOR COVID-19. Exciting to have Paxlovid but it is like the first generation PIs for HIV (200mg of ritonavir); more PIs are coming for SARS-CoV-2 which we can use to protect those with COVID at risk of severe disease from progressing https://t.co/rxGoQcanhf
Great overview, and should be noted that ease of synthetic scale-up and formulation (at least for preclinical studies) were even taken into account as factors in the clinical candidate decision at https://t.co/yPMpAvOlcD https://t.co/YribuTdrOi https://t.co/TJ2Jh4YsK3
Nirmatrelvir (PF-07321332) is an antiviral targeting SARS CoV-2-3 chymotrypsin-like cysteine protease enzyme (Mpro), a target for viral replication. PF-00835231 potently inhibits recombinant SARS-CoV1 Mpro and an important parent molecule. #IDJClub https://t.co/rGk4EJnnNZ
https://t.co/qp5s0ufYT8 ファイザーの経口摂取可能なコロナ治療薬PF-07321332 (パクスロリド) これからは治療薬が必要になるからね 本当に素晴らしい 代謝安定性が低いからリトナビル併用で 少し制限があるけど しっかりと血中濃度が維持されて活性がある
In this video, Dr. Susan Oliver and Julie the dog continue their discussion on science mistakes related to ivermectin. They address misunderstandings about its effectiveness, the importance of understanding scientific…
This installment of the Synthesis Workshop features Matthew Perry from AstraZeneca discussing advancements in medicinal chemistry. Highlights include the promising oral medication PF07321332, identified as a treatment…
@ValerieAnne1970 Paxlovid used MRC-5 in testing: https://t.co/u7shwov1BC and https://t.co/7J2WTPCqnu
RT @AlbertBourla: Wonderful to see the design and preclinical profile of @Pfizer's SARS-CoV-2 protease inhibitor, our new tool in the battl…
RT @MatthewHorwitz1: HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathlee…
RT @MatthewHorwitz1: HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathlee…
RT @MatthewHorwitz1: HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathlee…
RT @MatthewHorwitz1: HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathlee…
RT @MatthewHorwitz1: HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathlee…
RT @MatthewHorwitz1: HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathlee…
RT @MatthewHorwitz1: HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathlee…
RT @MatthewHorwitz1: HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathlee…
RT @MatthewHorwitz1: HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathlee…
RT @MatthewHorwitz1: HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathlee…
HUGE NEWS!!! Our (free) Med Chem Crash Course with Dr. Matthew Perry @AstraZeneca is out today!! Big thanks to Kathleen Cheasty for hosting and editing! Parts 1-3: https://t.co/BFnAStQVVn https://t.co/mFovLERF35 https://t.co/Wo7cnPQ8OF https://t.co/QQwcjFNP8R
RT @JakeYeston: We don’t often put small molecules on the cover of @ScienceMagazine but the paxlovid development story (handled with inspir…
RT @chris_idol_md: https://t.co/yeog4RQWXN
https://t.co/yeog4RQWXN
The image of nirmatrelvir (one of two molecules in Paxlovid) is from here: https://t.co/DaRzINPO1B Engines of Creation quote copied from here: https://t.co/s1FzxRH7Tn
RT @souyakuchan: COVID-19 新薬シムノトレルビルの構造ベース設計の報告。ニルマトレルビルの最初の報告 (https://t.co/8xoZKUEy3U) とは違って、特に包み隠すことなくボセプレビルからスタートしていると書かれている。 https://t…
COVID-19 新薬シムノトレルビルの構造ベース設計の報告。ニルマトレルビルの最初の報告 (https://t.co/8xoZKUEy3U) とは違って、特に包み隠すことなくボセプレビルからスタートしていると書かれている。 https://t.co/cvaUYEOPkx
Ritonavir is thus used to deliberately inhibit CYP3A4 and perpetrate a DDI on nirmatrelvir, effectively boosting the PK of the latter to therapeutic levels. It’s a marriage of convenience that turns an also-ran molecule into a drug. 7/ https://t.co/SfgD9XovV0
RT @baym: With MERS trending again (deep sigh) let's not forget: 1) It doesn't appear to transmit human-human asymptomatically 2) mRNA vacc…
With MERS trending again (deep sigh) let's not forget: 1) It doesn't appear to transmit human-human asymptomatically 2) mRNA vaccines are easily updatable to work on it and are already likely somewhat cross-protective 4) Paxlovid very likely still works: https://t.co/KU48J75yhM
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
La 'tijera molecular' que libera estas proteínas se llama proteasa. Si estas proteínas no están separadas entre sí por la proteasa, el virus se vuelve defectuoso. Paxlovid toma la proteasa y la neutraliza y evita que el virus se replique. https://t.co/vLWB9YKr6f
RT @AliNouriPhD: 4/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 4/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 4/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 4/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 4/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 4/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 4/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 4/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
4/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each other by the protease the virus becomes defective. Paxlovid grabs the protease and neutralizes it & stops the virus from replicating. https://t.co/fTC1PZxqGP
@_KJKelly @USMortality Indeed. It has nothing to do with HIV. Ritonivir (RTV) slows the metabolism of the anti-viral compound PF-07321332 (nirmatrelvir), ensuring its concentration remains high enough to be effective significantly longer then it would otherwise. https://t.co/l4atFgXMND https://t.co/tMYCu3khB4
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 https://t.co/tW3U2wXGs3
ουσιαστικά αβλαβής για υγιή άτομα και παιδιά πιθανότατα δεν είναι αυτό που θα συνιστούσα. Εσείς αποφασίζετε. Και διαβάστε τις παραπομπές. :)
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @AliNouriPhD: 3/The 'molecular scissor' that frees up these proteins is called a protease. If these proteins aren't separated from each…
RT @Dan_Landry: Paxlovid is made up of two drugs; nirmatrelvir and ritonavir. 1- Nirmatrelvir is the part that's active against SARS-CoV-2.…
RT @Dan_Landry: Paxlovid is made up of two drugs; nirmatrelvir and ritonavir. 1- Nirmatrelvir is the part that's active against SARS-CoV-2.…
Paxlovid is made up of two drugs; nirmatrelvir and ritonavir. 1- Nirmatrelvir is the part that's active against SARS-CoV-2. It's considered a protease inhibitor https://t.co/kTsi3ErpAR It helps to stop an early step in how the virus makes copies of itself
RT @MonicaGandhi9: PROTEASE INHIBITORS FOR COVID-19. Exciting to have Paxlovid but it is like the first generation PIs for HIV (200mg of ri…
RT @MonicaGandhi9: PROTEASE INHIBITORS FOR COVID-19. Exciting to have Paxlovid but it is like the first generation PIs for HIV (200mg of ri…
RT @MonicaGandhi9: PROTEASE INHIBITORS FOR COVID-19. Exciting to have Paxlovid but it is like the first generation PIs for HIV (200mg of ri…
RT @MonicaGandhi9: PROTEASE INHIBITORS FOR COVID-19. Exciting to have Paxlovid but it is like the first generation PIs for HIV (200mg of ri…
RT @MonicaGandhi9: PROTEASE INHIBITORS FOR COVID-19. Exciting to have Paxlovid but it is like the first generation PIs for HIV (200mg of ri…
RT @MonicaGandhi9: PROTEASE INHIBITORS FOR COVID-19. Exciting to have Paxlovid but it is like the first generation PIs for HIV (200mg of ri…
PROTEASE INHIBITORS FOR COVID-19. Exciting to have Paxlovid but it is like the first generation PIs for HIV (200mg of ritonavir); more PIs are coming for SARS-CoV-2 which we can use to protect those with COVID at risk of severe disease from progressing https://t.co/rxGoQcanhf
@PureRatPlgueBld @BerryTartlet @BreezerGalway @JoseGonzalesZa1 @SwaledaleMutton Apart from the fact it does, as you can see below. Id be delighted if you could provude this data you claim shows different IC50 values? https://t.co/H9M4LGdM5g https://t.co/RurojL0IDH https://t.co/YfgCPbQ8ma https://t.co/Keo2r87Nzl https://t.co/2nbKJpkE2b
Nirmatrelvir (PF-07321332) is an antiviral targeting SARS CoV-2-3 chymotrypsin-like cysteine protease enzyme (Mpro), a target for viral replication. PF-00835231 potently inhibits recombinant SARS-CoV1 Mpro and an important parent molecule. #IDJClub https://t.co/rGk4EJnnNZ
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 SCIENCE • 2 Nov 2021 • Vol 374, Issue 6575 • pp. 1586-1593 https://t.co/ukOwkmoynM
RT @HironoriFunabi1: 臨床試験で重症化防止に極めて高い効果を示したPfizerの抗新型コロナウイルス薬であるが、その開発には奥深い科学の叡智が集積された結果であることが最近Science誌で公開された論文で知ることができる。とても勉強になったので少し紹介して…
ニルマトレルビルは主にCYP3A4で代謝されるため、CYP3A4阻害剤である低用量(100mg)のリトナビルを併用することでニルマトレルビルの薬物動態が増強されます。 https://t.co/og1u33nB1m https://t.co/DC2WI0d74X
ニルマトレルビルは、in vitroにおいて広範囲のコロナウイルスのMpro活性とウイルス複製を強く阻害し、またマウスへの経口投与においてはSARS-CoV-2肺力価を偽薬よりも有意に低下させました。 https://t.co/og1u33nB1m
ニルマトレルビル(Nirmatrelvir/PF-07321332)は、SARS-CoV-2の3-キモトリプシン様システインプロテアーゼ(Mpro)を標的とする経口抗ウイルス薬*です。 https://t.co/og1u33nB1m
RT @AlbertBourla: Wonderful to see the design and preclinical profile of @Pfizer's SARS-CoV-2 protease inhibitor, our new tool in the battl…
RT @JMarcVX: Pfizer's #Paxlovid significantly reduces the viral load for all #SARSCoV2 variants, but also for #SarsCov1 and #MersCov. It's…
RT @nekonekoz: An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 https://t.co/8nKWSHhnmJ
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 https://t.co/8nKWSHhnmJ
@eemoin The nirmatrelvir otherwise has a T1/2 of 20 minutes… https://t.co/qiwJAhPCjB@
RT @PeterWark1710: Nirmatrelvir and ritonavir called paxlovid. Nirmatrelvir blocks the action of an enzyme the virus uses to replicate whi…
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 https://t.co/7nEoKea2d2
RT @PeterWark1710: Nirmatrelvir and ritonavir called paxlovid. Nirmatrelvir blocks the action of an enzyme the virus uses to replicate whi…
Nirmatrelvir and ritonavir called paxlovid. Nirmatrelvir blocks the action of an enzyme the virus uses to replicate while ritonavir boosts the levels of nirmatravir to maintain its effectiveness https://t.co/kACYwWE9np
@ImperialNHLI Really fantastic talk! thanks to the organisers also for an excellent symposium! Here is a link to the original publication by Dr. Owen and colleagues: https://t.co/u9ntc6C8Oj
4/ ¿Qué es Paxlovid? El segundo componente, ritonavir, es un inhibidor potente de la isoenzima del citocromo CYP3A4. Uso previo y amplio en terapia antiviral VIH. Mismo objetivo: mejorar vida media y niveles de fármaco activo en plasma. https://t.co/NenDoIesjf
(358) Here is an excellent research report on the development of a SARS-CoV-2 Mpro inhibitor called Pfizer PF-07321332. The marketeers call it PAXLOVID. How do you make Protease Inhibitors Selective? You use some amazing structural chemistry tools. https://t.co/2WDKDLVgjP https://t.co/EFn8lDffmX
RT @AlbertBourla: Wonderful to see the design and preclinical profile of @Pfizer's SARS-CoV-2 protease inhibitor, our new tool in the battl…
RT @FlangerOfTowels: @ASPphysician https://t.co/WdHtrFr096
RT @AlbertBourla: Wonderful to see the design and preclinical profile of @Pfizer's SARS-CoV-2 protease inhibitor, our new tool in the battl…
@ASPphysician https://t.co/WdHtrFr096
paper https://t.co/kHKg8KzEsf 臨床數據 https://t.co/bK5eHgIEWJ
https://t.co/qp5s0ufYT8 ファイザーの経口摂取可能なコロナ治療薬PF-07321332 (パクスロリド) これからは治療薬が必要になるからね 本当に素晴らしい 代謝安定性が低いからリトナビル併用で 少し制限があるけど しっかりと血中濃度が維持されて活性がある
@ScienceMagazine paper: https://t.co/qGEoX8iboi
RT @AlbertBourla: Wonderful to see the design and preclinical profile of @Pfizer's SARS-CoV-2 protease inhibitor, our new tool in the battl…
Great overview, and should be noted that ease of synthetic scale-up and formulation (at least for preclinical studies) were even taken into account as factors in the clinical candidate decision at https://t.co/yPMpAvOlcD https://t.co/YribuTdrOi https://t.co/TJ2Jh4YsK3
https://t.co/dpogPjroDp
RT @laoneill111: Anti-viral drug Paxlovid makes the cover of Science magazine- promise in a pill indeed. https://t.co/efWZErqq06 https://t…
RT @laoneill111: Anti-viral drug Paxlovid makes the cover of Science magazine- promise in a pill indeed. https://t.co/efWZErqq06 https://t…
RT @JakeYeston: We don’t often put small molecules on the cover of @ScienceMagazine but the paxlovid development story (handled with inspir…
RT @EricTopol: The link to the paper on the discovery of Paxlovid in this issue. It's the first non-repurposed drug vs #SARSCoV2 to have cl…
RT @AlbertBourla: Wonderful to see the design and preclinical profile of @Pfizer's SARS-CoV-2 protease inhibitor, our new tool in the battl…
RT @laoneill111: Anti-viral drug Paxlovid makes the cover of Science magazine- promise in a pill indeed. https://t.co/efWZErqq06 https://t…
RT @laoneill111: Anti-viral drug Paxlovid makes the cover of Science magazine- promise in a pill indeed. https://t.co/efWZErqq06 https://t…
RT @JakeYeston: We don’t often put small molecules on the cover of @ScienceMagazine but the paxlovid development story (handled with inspir…
RT @laoneill111: Anti-viral drug Paxlovid makes the cover of Science magazine- promise in a pill indeed. https://t.co/efWZErqq06 https://t…
A new kid almost in town. Targeting polyproteins might be better than introducing mutations in the virus. https://t.co/jd4zpRhwcG
RT @AlbertBourla: Wonderful to see the design and preclinical profile of @Pfizer's SARS-CoV-2 protease inhibitor, our new tool in the battl…
RT @ScienceMagazine: A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the #SARSCoV2 main protease, a…
RT @ScienceMagazine: A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the #SARSCoV2 main protease, a…
RT @ScienceMagazine: A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the #SARSCoV2 main protease, a…
RT @ScienceMagazine: A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the #SARSCoV2 main protease, a…
RT @ScienceMagazine: A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the #SARSCoV2 main protease, a…
RT @ScienceMagazine: A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the #SARSCoV2 main protease, a…
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 https://t.co/mftwiAVA9L
RT @ScienceMagazine: A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the #SARSCoV2 main protease, a…
RT @ScienceMagazine: A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the #SARSCoV2 main protease, a…
RT @ScienceMagazine: A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the #SARSCoV2 main protease, a…